US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Regentis Biomaterials Ltd. Ordinary Shares
(NY:
RGNT
)
0.7186
-0.1214 (-14.45%)
Official Closing Price
Updated: 8:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regentis Biomaterials Ltd. Ordinary Shares
< Previous
1
2
3
Next >
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
March 17, 2026
Via
ACCESS Newswire
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
February 24, 2026
Via
ACCESS Newswire
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
February 19, 2026
Via
ACCESS Newswire
Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs
February 17, 2026
Via
ACCESS Newswire
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
February 04, 2026
Via
ACCESS Newswire
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
January 20, 2026
Via
ACCESS Newswire
Nano-Cap Regentis Biomaterials Stock Is Up Nearly 15% This Year: Why Retail Traders Are Swarming It
↗
January 16, 2026
Heading to close this week as its best week since IPO, RGNT has become a retail favorite with surging followers on Stocktwits.
Via
Stocktwits
Topics
Initial Public Offering
Intellectual Property
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
January 06, 2026
Via
ACCESS Newswire
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation
January 05, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
December 18, 2025
Via
ACCESS Newswire
Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product
December 08, 2025
Via
ACCESS Newswire
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
December 05, 2025
From
Regentis Biomaterials Ltd.
Via
GlobeNewswire
< Previous
1
2
3
Next >